INTRODUCTION
Hepatitis C virus (HCV) is an enveloped, positivesense, single-stranded RNA virus belonging to the Flaviviridae family (1) . Fifteen million people are infected with HCV worldwide (2) , and HCV is a major causative agent of severe liver diseases such as cirrhosis and hepatocellular carcinoma. Therefore, HCV infection is recognized as a major global healthcare burden (3) . Although recent HCV therapy with direct-acting antivirals agents that directly target HCV enzymes has remarkably improved treatment outcomes, drug-resistant viruses have emerged during these treatments (4, 5) , warranting the development of alternative antivirals that target host machinery involved in HCV infection.
Decades after the discovery of HCV in 1989, a robust cell culture system that allowed completion of the HCV life cycle was developed using an HCV-JFH1 strain in 2005 (6) (7) (8) . In in vitro infection systems, only Huh7-derived cell lines, which were originally isolated from human a hepatocellular carcinoma, have been found to be highly permissive to HCV (9, 10) . Accordingly, Huh7 cells have been frequently used in studies of HCV infection (10) . In addition, Blight et al. established an Huh7.5 cell line highly permissive to HCV replicons (11) , and the subsequent Huh7.5.1 cell line was generat-ed from a cured HCV replicon cell line as a cell clone with a higher degree of permissiveness to HCV infection. These cells show viral titers of 10 4 -10 5 infectious units/ml of culture supernatant in the HCV-JFH1 infection system, and the virus can be serially passaged without loss of infectivity (8) . Very recent studies have also shown other hepatic and nonhepatic cell lines that endogenously or that exogenously express higher miR-122 levels and support HCV infection (12) (13) (14) (15) , although infection levels in these models are similar to or lower than those in Huh7-derived cells.
In the present study, cultured Huh7.5.1 cells had heterogeneous permissiveness to HCV infection. Thus, we isolated Huh7.5.1-derived cell clones using single-cell cloning and identified clones with higher and lower permissiveness to HCV infection. These established cell clones will contribute to further elucidation of the HCV life cycle and the development of novel antivirals and vaccines.
MATERIALS AND METHODS
Cell culture: Human hepatoma Huh-7.5.1 cells (8) were kindly provided by Dr. Francis V. Chisari (The Scripps Research Institute, La Jolla, CA, USA). Huh-7.5.1 cells and Huh-7.5.1-derived cell clones were maintained at 379 C in an atmosphere of 5z CO 2 in Dulbecco's modified Eagle's medium containing 10z fetal bovine serum (FBS), 0.1 mM nonessential amino acids, 100 U/ml penicillin G, and 100 mg/ml streptomycin sulfate (normal medium). Cells were usually passaged every 3-5 days at a density of ＞5 × 10 5 cells/ 10-cm dish.
Single-cell cloning: Huh7.5.1 cells were diluted in normal medium and were seeded into 10-cm dishes at 1,000 cells/dish. Cells were cultured until visible colonies formed, and colonies were isolated and re-cloned in 96-well plates using the limiting dilution method. Antibodies and plasmids: Rabbit monoclonal antibodies (mAbs) against scavenger receptor class B type I (SRBI; clone EP1556Y) and mouse mAbs against glyceraldehyde 3-phosphate dehydrogenase (GAPDH; clone 6C5) were purchased from Abcam, Plc. (Cambridge, UK). Rabbit anti-claudin-1 polyclonal antibodies and mouse anti-occludin mAbs (clone OC-3F10) were purchased from Life Technologies (Carlsbad, CA, USA). Mouse anti-CD81 mAbs (clone JS-81) were purchased from BD Bioscience Pharmingen (San Jose, CA, USA). Mouse mAbs against the low-density lipoprotein receptor (LDLR; clone 15C8) were purchased from EMD Millipore (Billerica, MA, USA). Mouse mAbs against the HCV core protein (clone 2H9) were described previously (6) . The human CD81 expression vector pcDNA3.1-hCD81 was generously provided by Dr. Y. Matsuura (Osaka University, Osaka, Japan).
Infection of cells with HCV: Huh7.5.1-derived cell cultures were infected with HCV-JFH1 (genotype 2a; HCVcc; 6). In brief, cells were incubated with HCVcc diluted in normal medium for 2 h at 379 C as described previously (16) . Viral titers were then determined using fluorescent focus assay as described by Kato et al. (17) , except for the use of Huh7.5.1-8 cells, as detailed below.
Immunofluorescence analysis: Immunofluorescence staining with mAb against the HCV core protein was performed as described previously (16) . In brief, cells were cultured on collagen-coated glass cover slips (Asahi Glass Co., Ltd., Tokyo, Japan) in 24-well plates and were fixed with 3.7z formaldehyde in phosphatebuffered saline (PBS) for 30 min. After washing with PBS containing 30 mM glycine, cells were permeabilized with PBS containing 0.1z Triton X-100 for 10 min, blocked with 5z (w/v) skim milk in PBS for 30 min, incubated with a 1:500 dilution of mouse mAbs against the anti-HCV core protein (2H9), and then incubated with1:500 dilutions of Alexa488-conjugated goat antimouse IgG (Life Technologies) and 4′ ,6′ -diamidino-2phenylindole (DAPI, 10 mg/ml, Life Technologies). Stained cells were observed under a fluorescence microscope (Biozero BZ-8100; Keyence Corp., Osaka, Japan).
Quantification of HCV RNA: Total RNA from culture supernatants and cultured cells was extracted and purified using the Viral Nucleic Acid Extraction Kit I and a Blood/Cultured Cell Total RNA mini Kit (FAVORGEN Biotech Corp., Pingtung City, Taiwan), respectively. Viral RNA contents were determined using one-step quantitative real-time reverse transcriptasepolymerase chain reaction (qRT-PCR) with RNAdirect TM Realtime PCR Master Mix (Toyobo Co. Ltd., Osaka, Japan), the specific primers 5′ -ACGGGGTTAA TTATGCAACAGG-3′ and 5′ -ACGGTGATGCAGGA CAACAG-3′ , and the Taqman probe Replication activity assays with subgenomic replicons: The subgenomic replicon plasmids pSGR-JFH1/Luc and pSGR-JFH1/Luc-GND (18) carried the luc gene and were based on the HCV-JFH1 sequence. The latter contained a GDD-to-GND mutation in NS5B that abolishes RNA polymerase activity, and it was linearized and transcribed in vitro into RNA using T7 RNA polymerase. Replicon RNA was then purified as described previously (18) using the AmpliScribe TM T7 High Yield Transcription Kit (Epicentre Biotechnologies, Madison, WI, USA). Cells were seeded in 24-well plates at 1 × 10 5 cells and were cultured for 1 day, and replicon RNA (2 mg each) from pSGR-JFH1/Luc or pSGR-JFH1/Luc-GND was transfected into cells using DMRIE-C Transfection Reagent (Life Technologies). After culture for 4 h, the culture medium was discarded and replaced with fresh normal medium, and cells were incubated for 1-4 days. Subsequently, the cells were lysed in 100 ml of Cell Culture Lysis Reagent (Promega Corp., Madison, WI, USA) and 5-ml aliquots were mixed with 25 ml of Luciferase assay substrate (PicaGene, Toyo Ink Mfg. Co., Ltd., Tokyo, Japan) for measuring the luciferase activity using a Luminescencer-PSN luminometer (ATTO Co., Ltd., Tokyo, Japan).
Infection of cells with HCV pseudo-particles: HCV pseudo-particles (HCVpp) were generated as described previously (19) . In brief, a Gag-Pol packaging vector (Gag-Pol 5349), a reporter vector (Luc 126), and an envelope glycoprotein (HCV E1 and E2)-expressing vector (JFH1, genotype 2a; TH, genotype 1b (20)) were transfected into HEK293T cells. After culture, medium from transfected cells was collected and used as the HCVpp stock.
Prior to infection, cells were seeded at a density of 5 × 10 4 cells/well in 48-well plates, cultured for 1 day, and then incubated with HCVpp for 6 h at 379 C. After washing 3 times with normal medium, cells were cultured in normal medium for an additional 2 days at 379 C. Luciferase activity in cell lysates was then measured as described above in the``Replication activity assays with subgenomic replicons'' section. Flow cytometry analyses: Cells were detached using PBS containing 1 mM ethylenediaminetetraacetic acid and then treated with anti-CD81 or anti-SRBI antibodies at a dilution of 1:500 in PBS containing 2z FBS for 30 min at 49 C. After washing with PBS, the cells were incubated with AlexaFluor 488 goat anti-mouse or anti-rabbit IgG (Life Technologies) at a dilution of 1:1,000 in PBS containing 2z FBS for 30 min at 49 C. Cells were then analyzed using a FACSCalibur flow cytometer (BD Biosciences, Franklin Lakes, NJ, USA) and CellQuest Pro software (BD Biosciences).
Immunoblot analysis: Immunoblotting was performed as described previously (16) . In brief, cell lysates containing equal amounts of protein were separated using sodium dodecyl sulfate-polyacrylamide gel electrophoresis and transferred onto polyvinylidene difluoride membranes and probed with the following antibodies: anti-SRBI (dilution, 1:1,000), anti-GAPDH (dilution, 1:20,000), anti-claudin-1 (dilution, 1:2,000), anti-occludin (dilution, 1:1,000), horseradish peroxidase (HRP)-conjugated goat anti-rabbit IgG (Jackson ImmunoResearch Laboratories, Inc., West Grove, PA, USA), and HRP-conjugated goat anti-mouse IgG 
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A Highly Permissive Cell Line for HCV Infection (Jackson ImmunoResearch Laboratories; dilutions, 1:2,000). Immunoreactive proteins were detected using the electrochemiluminescence system (GE Healthcare UK Ltd., Little Chalfont, Buckinghamshire, UK). Protein band intensities were quantified using Image J 1.45 software (NIH). RNA sequence analysis: Total RNA from Huh7.5.1 and Huh7.5.1-8 cells was purified using the RNAeasy Mini Kit (Qiagen K.K., Tokyo, Japan), and mRNA was enriched using the FastTrack MAG micro mRNA isolation kit (Invitrogen) according to the manufacturer's instructions. Subsequently, cDNA libraries were synthesized from 10 ng aliquots of enriched mRNA using the ScriptSeq TM v2 RNA-Seq Library Preparation Kit (Epicentre Biotechnologies) with 15 cycles of amplification according to the manufacturer's instructions. RNA-seq libraries were then electrophoresed on 1z agarose gels, and band sizes of 250-500 bp were selected to include specific adapters. Libraries were purified using the Wizard  SV Gel and PCR Clean-Up System (Promega). RNA-seq experiments (Takara Bio Inc., Shiga, Japan) were performed using the Illumina Hiseq 2500 with Rapid run mode (2 × 150-mer paired-end runs, 96,686,180 × 2 reads for Huh7.5.1 cells, and 89,522,470 × 2 reads for Huh7.5.1-8 cells). Data were analyzed using CLC Genomics Workbench 6.5 software (Qiagen K.K.) and were scaled using global normalization. Reads Per Kilobase of exon model per million mapped reads were estimated for each transcriptome.
Nucleotide sequence accession number: The RNA-seq short reads have been deposited in the DDBJ Sequence Read Archive of Japan (accession numbers: DRA002252).
Other methods: Plasmid transfection was performed using X-treme GENE HP Transfection Reagent (Roche). Protein concentrations were measured using BCA Protein Assay Reagent (Thermo Fisher Scientific, Inc., Waltham, MA, USA) with bovine serum albumin as a standard. Statistical analyses were performed using the t-test with the GraphPad calculator (http://www. graphpad.com/quickcalcs/), and differences were considerd significantly at P ＜ 0.01.
RESULTS
Huh7.5.1 cells exhibited heterogeneous HCV infection phenotypes: Cultured Huh7.5.1 cells were infected with varying copy numbers of HCVcc (1.14 × 10 7 and 1.14 × 10 8 copies/ml), and ratios of cells with visible staining of the HCV core protein were similar (38z and 35z, respectively; Fig. 1 ).However, HCV core protein staining varied between infected cells ( Fig. 1) , indicating phenotypic heterogeneity of HCV infection among these Huh7.5.1 cells.
Isolation of a highly HCV permissive Huh7.5.1-derived cell clone: To establish an Huh7.5.1 cell clone highly permissive to HCV, we isolated Huh7.5.1-derived cell clones using single-cell cloning as described in the Materials and Methods. Cloned cells were then infected with HCVcc, and cell lysates were examined using immunoblotting analyses with an anti-HCV core protein mAb. Cell clones exhibited varying expression levels of the HCV core protein, producing variable HCV permissiveness among clones (Fig. 2) , as indicated in Fig. 1 . Subsequently, a highly permissive clone was designated Huh7.5.1-8, and higher HCV growth rates were shown (Fig. 2, lane h) . Infection of Huh7.5.1-8 cells with HCVcc at 1.14 × 10 7 copies/ml produced intense anti-HCV core protein staining in all cells (Fig.  3B ). However, no morphological differences were ob- Figs. 4A and 4B) . Examination of infectivity titers in culture supernatants from cell strains at 4 dpi showed 4.56 × 10 6 ± 2.61 × 10 5 focus-forming units (ffu)/ml of culture supernatant from Huh7.5.1-8 cells, which was more than 10-fold higher than that of Huh7.5.1 cells (Table 1 ). However, numbers of ffu per 10 5 HCV RNA copies did not differ between Huh7.5.1 and Huh7.5.1-8 cells (105 ± 6 vs. 69 ± 4; Table 1 ), indicating that both cells produced viral particles with comparable infectivity.
To identify steps in the HCV life cycle that were enhanced in Huh7.5.1-8 cells, transient-replication assays were performed using a subgenomic replicon carrying the luciferase reporter gene SGR-JFH1/Luc-wt (21) . As shown in Fig. 5 , luciferase activity in replicon-transfected Huh7.5.1-8 cells progressively increased for 2 days and then reached a plateau, whereas that in the replicon- 
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A Highly Permissive Cell Line for HCV Infection transfected Huh7.5.1 cells gradually increased and reached a plateau at day 3. In subsequent experiments, the replication-incompetent mutant of the replicon, SGR-JFH1/Luc-GND (21) showed similar background levels of luciferase activity in both cell strains, confirming that observed increases in activity were dependent on viral RNA replication. These results indicate more than 10-fold greater HCV RNA replication activity in Huh7.5.1-8 cells than in parental Huh7.5.1 cells.
In further experiments, HCV entry activity was determined in these cells using HCVpp, which carries a lu-ciferase reporter gene (19) . At 2 dpi, luciferase activity of Huh7.5.1 cells infected with HCPpp (genotype 2a of 1b) was approximately half of that of Huh7.5.1-8 cells (Fig. 6A ), suggesting the presence of cell subpopulations with relatively lower HCV entry activity among Huh7.5.1 cells. HCV entry into host cells is mediated by multiple host factors, including CD81, SRBI, claudin-1, occludin, and LDLR (22) (23) (24) (25) . Immunoblot analyses revealed no differences in protein levels of SRBI, claudin-1, occludin, or LDLR between Huh7.5.1 and Huh7.5.1-8 cells, whereas lower CD81 protein expres- Table 2 . . After 2 days, the cells were infected with HCVcc at 1.14 × 10 9 copies/ml. At 4 dpi, the cells were stained with anti-HCV core protein mAb (green) and DAPI (blue) and observed by fluorescence microscopy. Bar, 100 mm.
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sion was observed in Huh7.5.1 cells (Fig. 6B ). In agreement, flow cytometry analyses showed that a significant portion of Huh7.5.1 cells was deficient in CD81 ( Fig.  6C) , which is essential for HCV infection (22) . These data suggest that the reduction in HCV infection of Huh7.5.1 cell subpopulations was partly because of CD81 deficiency. However, uniform and stable CD81 expression was observed in Huh7.5.1-8 cells (Fig. 6C ), and phenotypes of increased cellular permissiveness to HCV were stable in Huh7.5.1-8 cells, even after 100 passages over 1 year. Collectively, the present observations indicate that Huh7.5.1-8 cells have relatively higher viral replication activity and are stable and highly permissive to HCV infection. To identify characteristic host factors of Huh7.5.1-8 cells with higher viral replication activity, we compared Huh7.5.1 and Huh7.5.1-8 cells by RNA-seq analyses using the Illumina Hiseq Ultra-High-Throughput Sequencing System and selected genes with expression levels that differed by ＞1.5 fold between cell types (P ＜ 0.01, Bonferroni test and a false discovery rate [FDR]) ( Table 2 ). Seven upregulated genes were identified in Huh7.5.1-8 cells, including neurotensin (NTS), anterior gradient 2 (AGR2), group-specific component (GC), alpha-fetoprotein (AFP), albumin (ALB), ribosomal protein L39 (RPL39), and sec61 gamma subunit (SEC61G). However, no genes were expressed at lower levels in Huh7.5.1-8 cells than in Huh7.5.1 ( Table 2 ). In subsequent real-time qRT-PCR experiments, differences in mRNA expression reflected those identified in RNAseq analyses, and all, except RPL39, upregulated, suggesting an involvement in enhanced viral replication in Huh7.5.1-8 cells (Fig. 7) .
Huh7.5.1-5 cell clones were CD81 deficient and HCV nonpermissive: In addition to the Huh7.5.1-8 cell clone, another clone that was not permissive to HCV infection (Huh7.5.1-5) was isolated (Fig. 2, lane e) . Huh7.5.1-5 cells also resisted entry of HCVpp (Fig. 6A ) and were deficient in CD81 ( Figs. 6B and 6C ). In addition, HCV infectability was restored after the expression of human CD81 in Huh7.5.1-5 cells (Fig. 8 ). In agreement with previous studies (22, 26) , the present data indicate that CD81 is essential for HCV infection in hepatocytes (22, 26) .
DISCUSSION
Under the present culture conditions, Huh7.5.1 cells showed heterogeneous phenotypes for HCV infection, as shown in previous studies of phenotypically distinct Huh7 cell lines (11, (27) (28) (29) (30) (31) (32) (33) . Because Huh7-derived cells were originally derived from a human hepatocellular carcinoma, their genomes may be unstable. Accordingly, gene expression levels varied between parental Huh7.5.1 cells and cloned cells ( Table 2 and Fig. 7) . Following single-cell cloning, we isolated an Huh7.5.1-8 cell clone highly permissive to HCV infection, with cellular HCV RNAs of ＞10 9 copies/mg of total RNA (13fold higher) and viral titers of ＞4 × 10 6 infectious units/ml of culture supernatant (11-fold higher). In addition, the HCV infection phenotype was very stable in Huh7.5.1-8 cells, indicating their utility in studies of reproductive HCV infection.
Higher HCV permissiveness of Huh7.5.1-8 cells was reflected by higher replication activity of HCV ( Fig. 5 ) in these cells. In addition, sustained expression of HCV entry factors, particularly CD81, resulted in complete entry of HCV into Huh7.5.1-8 cells, likely contributing to their HCV permissiveness (Fig. 6 ). RNA-seq and qRT-PCR analyses identified significant differences in 6 gene transcript levels (NTS, AGR2, GC, AFP, ALB, and SEC61G) between Huh7.5.1 and Huh7.5.1-8 cells ( Table 2 and Fig. 7 ). Among these, the hepatocytespecific genes AFP, ALB, and GC, a member of the albumin gene family, were upregulated, suggesting that Huh7.5.1-8 cells have more differentiated hepatocytelike phenotypes that are favorable for HCV infection (15, 29, (34) (35) (36) . Girard et al. previously showed that NTS is highly upregulated in HCV NS5A-expressing Huh7 cells (37) and may be associated with efficient HCV replication. The genes NTS and AFP are also known to be upregulated in hepatic tumors (38, 39) , and the protein SEC61G is required for tumor cell survival (40) . In addition, AGR2 acts as a p53 tumor suppressor inhibitor (41) . Thus, higher expression levels of these genes may facilitate the growth of Huh7.5.1-8 cells. Because HCV replication is known to vary between stages of cell growth (42) (43) (44) , further investigations of the 6 genes identified in the present study are required to determine their roles in the HCV life cycle, including RNA replication.
In a previous study, Akazawa et al. isolated several CD81-deficient Huh7 clones (26) . Thus, we established a CD81-deficient Huh7.5.1-5 cell clone from the present Huh7.5.1 cells, which were heterogeneous. Moreover, although the CD81 gene may be unstable in Huh7 hepatoma cells and their descendants (33), CD81-defecient cells were likely selected under the present culture conditions.
In conclusion, we isolated Huh7.5.1-derived subclones with varying HCV permissiveness, including a highly HCV-permissive Huh7.5.1-8 cell clone with higher replication activity and an HCV-nonpermissive Huh7.5.1-5 cell clone deficient in CD81. HCV infection was easily detected using immunohistochemical, immunoblotting, and qRT-PCR analyses of Huh7.5.1-8 cells. Although the mechanisms underlying increased HCV replication activity in Huh7.5.1-8 cells remain unknown, these isolated cell clones provide a model of HCV infection that is widely applicable to drug screening studies and may facilitate detailed investigations of the HCV life cycle.
